risk/reward analysi
edt pm bst
barclay capit inc and/or one affili seek busi compani cover research report result investor awar firm
may conflict interest could affect object report
investor consid report singl factor make invest decis
share come pressur sinc sept around esmo
declin vs nbi index
given recent trade rang view valuat reflect
jakafi baricitinib royalti cash aka base busi nomin
epacadostat
go data see like scenario ahead readout
data strongli posit npv pt stock reflect
valu melanoma addit upsid indic nsclc rcc etc
data modestli posit npv less upsid melanoma
lower expect indic
data neg npv downsid stock trade base
valuat jakafi baricitinib net-cash minim pipelin valu
overal view risk/reward profil share attract
nomin valu epacadostat current almost valu rest
pipelin contain number differenti oncolog candid
sinc esmo share declin vs nbi
share perform jan present
phase trial complet
announc progress phase
assess current valu driver
base analysi discuss mani investor
barclay analysi breakdown current
valu stock
neg sentiment potenti weigh
concern level esmo
ratio cr pr posit rel
neg patient
perceiv shift tone manag
partner regard data
interim analysi taken
emphasi sub-group/ biomark analysi
perhap suggest benefit may
restrict specif group
partner intern program bristol
cross-trial comparison challeng
compar favor
opdivo yervoy result orr median month
dose
moreov addit epacadostat keytruda seem
posit net effect sever endpoint
trial differ asid epacadostat increas orr primarili rais pr
seem lengthen patient mo
dose
ahead data evalu three
strongli posit epacadostat merck
soc bristol
orr median month
ahead data
data track
anticip result top-lin
perhap chicago il
modestli posit combin provid line
pfs/o benefit upsid limit distinct sub-
orr line median
neg provid
meaning benefit upsid extrem restrict
small sub-popul
orr month line kn-
clinic benefit restrict small subgroup
data strong epacadostat launch melanoma outlook
mf pv continu robust uptak
licens nv nda
epacadostat data orr median
melanoma po increas npv
indic po rise nsclc
renal bladder combin npv
risk adjust sale
invest agenu
data modest epacadostat still launch melanoma though upsid
reduc develop continu within indic
assumpt remain level
epacadostat data modest orr line
melanoma po increas npv declin
penetr melanoma market declin
indic po indic increas
upsid case npv
invest agenu
risk-adjust sale
fail show benefit vs pembro monotherapi see limit
downsid npv share
assumpt remain level
epacadostat data neg orr
month line clinic benefit
restrict small subgroup
melanoma contribut indic complet
remov model
invest agenu
indic po indic declin essenti
littl valu ascrib ido inhibitor
zero valu entir pipelin
capmatinib nsclc licens novarti nda expect multipl phase nhl studi
barclay research number may total due round
analyst certif import disclosur
